A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumors (GIST)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2017 Results comparing nocebo effects in older patients (n=446) enrolled in cancer therapeutic trials (NCCTG97-24-51 and ACOSOG Z9001), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
19 Jun 2012 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov.(Parent trial: NCT00041197).
19 Jun 2012 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov.(Parent trial: NCT00041197).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com